Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
Alzamend Neuro (ALZN) announced it has regained compliance with Nasdaq's listing standards, meeting the minimum stockholders' equity requirement of $2.5M. The company reported $5.8M in equity as of July 31, 2026. This follows a previous non-compliance notice in March 2026, which the company addressed with a submitted plan. The CEO expressed focus on advancing clinical trials for AL001 in partnership with Massachusetts General Hospital.
How this was made

The 30-second read
Why it matters
Regaining Nasdaq compliance eliminates a potential delisting threat, which could stabilize the share price.
Market read
The news is a primary corporate action for ALZN, removing a regulatory risk but offering limited immediate trading impetus.
What to watch
The announcement does not address upcoming clinical trial results, which remain the primary catalyst.
Background
Alzamend Neuro is a clinical‑stage biopharma focused on neuro‑psychiatric disorders.
Ticker impact
Alzamend Neuro announced it regained compliance with Nasdaq Listing Rule 5550(b)(1) after meeting the $2.5M equity requirement.
Potential modest upside as investors view the listing security favorably.
The company cleared a regulatory hurdle; no new financing or product data was disclosed.
Market effects
May improve perception of compliance risk for small‑cap biotech listings.
Limited to US Nasdaq market; no broader regional effect.
Minimal global impact; primarily a company‑specific regulatory update.
Counterpoint
Investors may view the compliance fix as a one‑time event and remain cautious on valuation.
Key entities
- CompanyAlzamend Neuro, Inc.
Clinical‑stage biopharma listed on Nasdaq (ALZN).
- RegulatorNasdaq Listing Qualifications Staff
Issued the compliance notice confirming ALZN meets equity requirements.
